A phase IV, multicentre, open‐label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures-Reference-Cited by-同舟云学术

A phase IV, multicentre, open‐label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures

Published:2022-05-05 Issue:4 Volume:28 Page:
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Escobar Miguel¹,Dunn Amy²,Quon Doris³,Trzaskoma Ben⁴,Lee Lucy⁴,Ko Richard H.⁴,Carpenter Shannon L.⁵

Affiliation:

1. University of Texas Health Science Center Houston Texas USA

2. Nationwide Children's Hospital Columbus Ohio USA

3. Orthopedic Hemophilia Treatment Center Los Angeles California USA

4. Genentech, Inc. South San Francisco California USA

5. Children's Mercy Hospital Kansas City Missouri USA

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14574

Reference10 articles.

1. WFH Guidelines for the Management of Hemophilia, 3rd edition

2. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens

3. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

4. Definitions in hemophilia: communication from the SSC of the ISTH

5. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors;TH Open;2024-01

2. Methodological recommendations for surgical care in patients with hemophilia A receiving prophylactic therapy with emicizumab;Pirogov Russian Journal of Surgery;2024

3. Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center;Research and Practice in Thrombosis and Haemostasis;2023-08

4. Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance;HemaSphere;2023-06

5. CORR Insights®: What is the Effect of Bevacizumab on Cartilage and Synovium in a Rabbit Model of Hemophilic Arthropathy?;Clinical Orthopaedics & Related Research;2023-05-17